绿康生化(002868) - 2021 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2021 was ¥363,386,382.24, representing a 17.93% increase compared to ¥308,145,259.54 in 2020[21] - The net profit attributable to shareholders of the listed company for 2021 was -¥26,043,911.65, a decrease of 160.28% from ¥43,208,315.92 in 2020[21] - The net cash flow from operating activities was CNY 35,170,418.50, down 61.23% from CNY 90,720,874.01 in the previous year[22] - The total assets at the end of 2021 were CNY 1,258,398,896.70, representing a 29.40% increase from CNY 972,502,779.28 at the end of 2020[22] - The company's basic and diluted earnings per share were both CNY -0.17, a decline of 160.71% from CNY 0.28 in 2020[22] - The weighted average return on net assets was -3.53%, down from 5.68% in 2020[22] - In Q4 2021, the company reported a net profit attributable to shareholders of CNY -20,072,420.22, following a trend of losses in the latter half of the year[27] - The company reported a total profit loss of RMB -32,350,147.76 and a net profit loss attributable to shareholders of RMB -26,043,911.65, primarily due to rising raw material and energy costs[52] Business Operations - The company operates in the manufacturing of veterinary drugs and special chemical products, with no changes in its main business since 2018[20] - The company has engaged Lixin Certified Public Accountants as its auditing firm[21] - The company has not made any adjustments or restatements to previous years' accounting data[21] - The company has not reported any changes in its controlling shareholders since its listing[20] - The company has established stable partnerships with major clients including M.cassab, Shuanghui Development, and others, enhancing its market presence[47] - The company is focusing on the development of green and healthy veterinary raw materials and formulations to meet future market demands[53] Research and Development - The company has accumulated 17 invention patents and 15 utility model patents as of 2021, showcasing its strong commitment to research and development[45] - The company's R&D investment amounted to ¥24,821,183.37 in 2021, representing a 24.65% increase from ¥19,913,133.94 in 2020[75] - R&D personnel increased to 82 in 2021, a rise of 22.39% compared to 67 in 2020[75] - The company is currently developing several new products, including RD16 and RD19, aimed at enhancing market competitiveness and increasing sales[75] - The company is currently developing multiple new production processes aimed at optimizing costs and improving product quality[74] Market Trends and Opportunities - The global market for biopesticides is projected to grow from $3.3 billion in 2017 to $9.5 billion by 2025, with a compound annual growth rate (CAGR) of 15% to 18%[41] - The demand for safe, efficient, and low-residue veterinary drugs is increasing due to heightened food safety awareness globally, driving market growth[38] - The global population is expected to reach 8.5 billion by 2030, increasing the demand for meat, eggs, and dairy products, which benefits the animal health market[39] - The company is exploring new growth opportunities in the plant protection market amid challenges and opportunities in the agricultural sector[34] Environmental and Social Responsibility - The company has established a wastewater treatment workshop to handle wastewater, ensuring compliance with discharge standards[173] - The company reported a chemical oxygen demand (COD) discharge concentration of 21.17 mg/L, well below the standard of ≤60 mg/L[171] - The company has been actively involved in poverty alleviation, helping 17 families in 2021 with a total donation of CNY 33,400 through its charity fund[184] - The company supported rural infrastructure construction in three villages with a total funding of CNY 30,000 as part of its commitment to rural revitalization[186] - The company has implemented energy-saving measures, resulting in a continuous decrease in energy consumption indicators[180] Strategic Initiatives - The company plans to adjust the investment amount for the production project to not exceed ¥80 million, with the project expected to reach operational status by March 31, 2022[58] - The company is actively pursuing an "internal + external" growth strategy to achieve sustainable development[53] - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 200 million RMB allocated for potential mergers and acquisitions in 2022[136] - The company plans to expand its market presence in Southeast Asia, targeting a 25% increase in market share by 2023[130] Governance and Compliance - The company's governance structure complies with relevant regulations, ensuring independent operation and decision-making without interference from controlling shareholders[119] - The company maintains a clear ownership structure with independent assets, including land, factories, and equipment, ensuring no asset occupation by the controlling shareholder[121] - The company has established a complete independent human resources management system, with no interference from the controlling shareholder in personnel decisions[122] - The company has a fully independent supply, research and development, production, and sales system, allowing for autonomous market operations[122] Future Outlook - The company provided a positive outlook for 2022, projecting a revenue growth of 10% to 1.32 billion RMB[128] - New product launches are expected to contribute an additional 5% to revenue growth in the upcoming year, with two new products scheduled for release in Q2 2022[132] - The company aims to achieve a net profit margin of 12% by the end of 2021, up from 10% in 2020[146] - The company has set a performance guidance of 1.8 billion RMB in revenue for the next fiscal year, reflecting a 20% increase from the current year[191]